Woodline Partners LP Has $9.64 Million Holdings in Arcellx, Inc. (NASDAQ:ACLX)

Woodline Partners LP lifted its stake in Arcellx, Inc. (NASDAQ:ACLX - Free Report) by 13.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 125,649 shares of the company's stock after acquiring an additional 14,660 shares during the period. Woodline Partners LP owned 0.23% of Arcellx worth $9,636,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Headlands Technologies LLC bought a new stake in shares of Arcellx in the 4th quarter worth approximately $41,000. KBC Group NV raised its holdings in shares of Arcellx by 37.3% in the 4th quarter. KBC Group NV now owns 1,388 shares of the company's stock worth $106,000 after purchasing an additional 377 shares in the last quarter. Kazazian Asset Management LLC bought a new stake in shares of Arcellx in the 4th quarter worth approximately $204,000. Landscape Capital Management L.L.C. bought a new stake in shares of Arcellx in the 4th quarter worth approximately $214,000. Finally, Xponance Inc. raised its holdings in shares of Arcellx by 8.6% in the 4th quarter. Xponance Inc. now owns 3,088 shares of the company's stock worth $237,000 after purchasing an additional 244 shares in the last quarter. 96.03% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Arcellx

In other news, Director Kavita Patel sold 1,500 shares of the stock in a transaction on Tuesday, April 8th. The shares were sold at an average price of $57.50, for a total transaction of $86,250.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last quarter, insiders have sold 6,000 shares of company stock worth $377,655. 8.35% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Separately, Scotiabank dropped their target price on shares of Arcellx from $133.00 to $93.00 and set a "sector outperform" rating on the stock in a report on Friday, May 9th. Thirteen equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $111.33.

Arcellx Price Performance

Arcellx stock traded up $0.30 during trading hours on Wednesday, hitting $62.25. The company had a trading volume of 89,414 shares, compared to its average volume of 598,968. The firm has a market capitalization of $3.43 billion, a P/E ratio of -87.90 and a beta of 0.34. The firm's fifty day moving average is $61.97 and its 200-day moving average is $70.36. Arcellx, Inc. has a fifty-two week low of $47.86 and a fifty-two week high of $107.37.

Arcellx (NASDAQ:ACLX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.29). The company had revenue of $8.13 million during the quarter, compared to analyst estimates of $19.51 million. Arcellx had a negative net margin of 25.94% and a negative return on equity of 8.28%. Analysts anticipate that Arcellx, Inc. will post -1.58 earnings per share for the current year.

Arcellx Profile

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).